Jorge Garcia Borrega

Mr. Jorge Garcia Borrega

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2021 in Journal of Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
JNJan-Hendrik Naendrup
Jan-Hendrik Naendrup
JBJorge Garcia Borrega
Jorge Garcia Borrega
DEDennis Alexander Eichenauer
Dennis Alexander Eichenauer
ASAlexander Shimabukuro-Vornhagen
Alexander Shimabukuro-Vornhagen
MKMatthias Kochanek
Matthias Kochanek
BBBoris Bol̈l
Boris Bol̈l
Reactivation of viruses such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV) are common in critically ill patients and have been described in patients with severe COVID-19. However, it is unclear whether these reactivations are associated with increased mortality and whether targeted treatments are beneficial. In a retrospective single-center cohort study, patients with severe COVID-19 treated on our intensive care unit (ICU) were screened for EBV and CMV reactivation as detected by polymerase chain reaction. If present, patient characteristics, temporal connections to severe acute respiratory syndrome coronavirus 2 diagnosis and corticosteroid use, the use of targeted treatments as well as the course of disease and outcome were analyzed. As control group, non-COVID-19 patients with sepsis, treated within the same time period on our ICU, served as control group to compare incidences of viral reactivation. In 19 (16%) of 117 patients with severe COVID-19 treated on our ICU EBV reactivations were identified, comparable 18 (14%) of 126 in the non-COVID-19 control group (P = .672). Similarly, in 11 (9%) of 117 patients CMV reactivations were identified, comparable to the 16 (13%) of 126 in the non-COVID-19 sepsis patients (P = .296). The majority of EBV (58%) and CMV reactivations (55%) were detected in patients under systemic corticosteroid treatment. 7 (37%) of 19 patients with EBV reactivation survived the ICU stay, 2 (29%) of 7 patients with rituximab treatment and 5 (42%) of 12 patients without treatment (P = .568). Five (50%) of 10 patients with CMV reactivation survived the ICU stay, 5 (83%) of 6 patients with ganciclovir treatment and 0 of 4 patients without treatment (P = .048). Follow-up analysis in these patients showed that the initiation of treatment lead to decrease in viral load. Critically ill patients with COVID-19 are at a high risk for EBV and CMV reactivations. Whether these reactivations are a cause of hyperinflammation and require targeted treatment remains uncertain. However, in patients with clinical deterioration or signs of hyperinflammation targeted treatment might be beneficial and warrants further studying.

28 September 2022 in Intensive and Critical Care Nursing
Verified
Journal Article
Closed access
EREyleen Reifarth
Eyleen Reifarth
JBJorge Garcia Borrega
Jorge Garcia Borrega
Matthias KochanekMatthias Kochanek
Matthias Kochanek

25 January 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MSMoritz Schmidbauer
Moritz Schmidbauer
CFCaroline Ferse
Caroline Ferse
FSFarid Salih
Farid Salih
CKCarsten M. Klingner
Carsten M. Klingner
RMRita Musleh
Rita Musleh
OGon behalf of the IGNITE Study Group
on behalf of the IGNITE Study Group
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) profoundly impacts hemostasis and microvasculature. In the light of the dilemma between thromboembolic and hemorrhagic complications, in the present paper, we systematically investigate the prevalence, mortality, radiological subtypes, and clinical characteristics of intracranial hemorrhage (ICH) in coronavirus disease (COVID-19) patients. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we performed a systematic review of the literature by screening the PubMed database and included patients diagnosed with COVID-19 and concomitant ICH. We performed a pooled analysis, including a prospectively collected cohort of critically ill COVID-19 patients with ICH, as part of the PANDEMIC registry (Pooled Analysis of Neurologic Disorders Manifesting in Intensive Care of COVID-19). Results: Our literature review revealed a total of 217 citations. After the selection process, 79 studies and a total of 477 patients were included. The median age was 58.8 years. A total of 23.3% of patients experienced the critical stage of COVID-19, 62.7% of patients were on anticoagulation and 27.5% of the patients received ECMO. The prevalence of ICH was at 0.85% and the mortality at 52.18%, respectively. Conclusion: ICH in COVID-19 patients is rare, but it has a very poor prognosis. Different subtypes of ICH seen in COVID-19, support the assumption of heterogeneous and multifaceted pathomechanisms contributing to ICH in COVID-19. Further clinical and pathophysiological investigations are warranted to resolve the conflict between thromboembolic and hemorrhagic complications in the future.

10 February 2022 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
PKPhilipp Koehler
Philipp Koehler
SSSaskia von Stillfried
Saskia von Stillfried
JBJorge Garcia Borrega
Jorge Garcia Borrega
FFFrieder Fuchs
Frieder Fuchs
JSJon Salmanton-García
Jon Salmanton-García
OCOliver A. Cornely
Oliver A. Cornely
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, patients with acute respiratory distress syndrome (ARDS) due to SARS-CoV-2 showed a profoundly altered immune system and received immune-modulating therapeutic interventions. This enhanced the susceptibility for fungal superinfections [1, 2]. With the first reports of COVID-19-associated pulmonary aspergillosis (CAPA) the 2020 European Confederation of Medical Mycology (ECMM)/International Society for Human and Animal Mycology (ISHAM) consensus criteria were proposed [3, 4] and Aspergillus tracheobronchitis (ATB) was distinguished as a sub-entity in CAPA [4–6]. During bronchoscopy, ATB presents as ulcerations, pseudomembranes, plaques and eschars, possibly combined with tracheal stenosis [5]. Facing the risk of transmission and SARS-CoV-2 infection of examiners during bronchoscopy, blind suctioning of upper airway samples has been implemented with tracheal aspirates (TA) and non-bronchoscopic lavages. These techniques preclude inspection of the airways, so that ATB cannot be diagnosed beyond the level of suspicion. To study ATB in CAPA patients, we performed a retrospective, single-centre cohort study.

3 August 2023 in Intensive and Critical Care Nursing
Verified
Journal Article
Closed access
EREyleen Reifarth
Eyleen Reifarth
BBBoris Bol̈l
Boris Bol̈l
Matthias KochanekMatthias Kochanek
Matthias Kochanek
JBJorge Garcia Borrega
Jorge Garcia Borrega

7 March 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
JMJakob J. Malin
Jakob J. Malin
VCVeronica Di Cristanziano
Veronica Di Cristanziano
CHCarola Horn
Carola Horn
EPElisabeth Pracht
Elisabeth Pracht
JBJorge Garcia Borrega
Jorge Garcia Borrega
JRJan Rybniker
Jan Rybniker